Optimizing Clinical Supply Management With A One-Team Approach

If you're running global trials with a lean internal team, the math gets uncomfortable fast: more countries, more sites, more patients, and the same headcount trying to hold it all together. That was the reality for NewAmsterdam Pharma (NAP) as they advanced obicetrapib, their lead investigational compound, through 11 concurrent studies, three of which were pivotal Phase 3 trials spanning 51 countries and 835 clinical sites.

The supply chain challenge alone would give most ops teams pause. NAP needed reliable, on-time, in-full delivery of investigational medicinal products (IMPs) to support over 12,000 patients, while navigating a patchwork of country-specific regulatory requirements and keeping costs from spiraling.

What changed the trajectory was consolidating their contract development and manufacturing organization (CDMO) and contract research organization (CRO) support under one partner rather than managing multiple vendors. The integrated model meant fewer handoffs, clearer accountability, and a supply operation that could actually scale with trial demands.

Access the full case study to see the specific outcomes NAP achieved and how the one-team model held up under real Phase 3 pressure.